Back to News
Sep 16, 2025 4:00 PM

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims & Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum.

HIMS is encountering selling pressure. See the trading setup here.

The FDA flagged misleading claims made by Hims & Hers Health regarding its compounded semaglutide products. Semaglutide is an active ingredient in Novo Nordisk A/S’ (NYSE:NVO) flagship Wegovy and Ozempic.

In a warning letter, the FDA said the company's website promotes its semaglutide offerings with claims that imply equivalence to FDA-approved drugs, which the agency says is false and deceptive under federal law.

Also Read: Hims & Hers Faces FDA ...